CD8A and diffuse large B-cell lymphoma: Figure 6B demonstrated that DLBCL patients with a high-risk score showed decreased levels of CD8A, CTLA4, CXCL10, CXCL9, GZMA, HAVCR2, IDO1, and IFNG expression. Furthermore, the findings from the ESTIMATE analysis revealed that DLBCL patients with a low-risk score exhibited elevated ESTIMATE, immune, and stromal scores, while their tumor purity was comparatively lower (Figure 6C–6F).